Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease

BACKGROUND: This review describes the research and development process of gantenerumab, a fully human anti-amyloid monoclonal antibody in development to treat early symptomatic and asymptomatic Alzheimer’s disease (AD). Anti-amyloid monoclonal antibodies can substantially reverse amyloid plaque path...

Descripción completa

Detalles Bibliográficos
Autores principales: Bateman, Randall J., Cummings, Jeffrey, Schobel, Scott, Salloway, Stephen, Vellas, Bruno, Boada, Mercè, Black, Sandra E., Blennow, Kaj, Fontoura, Paulo, Klein, Gregory, Assunção, Sheila Seleri, Smith, Janice, Doody, Rachelle S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9707418/
https://www.ncbi.nlm.nih.gov/pubmed/36447240
http://dx.doi.org/10.1186/s13195-022-01110-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9707418/
https://www.ncbi.nlm.nih.gov/pubmed/36447240
http://dx.doi.org/10.1186/s13195-022-01110-8

Ejemplares similares